Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse

Figures & data

Table 1. Patient baseline characteristics.

	REC < 1.5% (N = 393)		REC ≥ 1.5% (N = 537)		Chi-Square test (p value)
	N of patients	%	N of patients	%
Median age (range)	59 (25–97)		62 (25–97)
ER Positive Negative Unknown	264 128 1	67.2% 32.6% 0.3%	412 122 3	76.7% 22.7% 0.6%	0.001
PgR Positive Negative Unknown	222 169 2	56.5% 43% 0.5%	344 188 5	64.1% 35% 0.9%	0.015
HER2 Positive Negative Unknown	84 305 4	21.4% 77.6% 1%	98 434 5	18.2% 80.8% 0.9%	0.232
Stage I II III Unknown	119 178 89 7	30.3% 45.3% 22.6% 1.8%	177 242 115 3	33% 45.1% 21.4% 0.6%	0.568
T stage 1 2 3 4 Unknown	159 146 33 52 3	40.5% 37.2% 8.4% 13.2% 0.8%	233 206 39 56 3	43.4% 38.4% 7.3% 10.4% 0.6%	0.526
N stage 0 1 2 3 Unknown	223 140 20 7 3	56.7% 35.6% 5.1% 1.8% 0.8%	321 161 39 13 3	59.8% 30% 7.3% 2.4% 0.6%	0.302
Lymphovascular invasion Yes No Unknown	92 167 134	23.4% 42.5% 34.1%	115 213 209	21.4% 39.7% 38.9%	0.320
Tumor grade 1 2 3 Unknown	59 179 138 17	15% 45.5% 35.1% 4.3%	111 229 173 24	20.7% 42.6% 32.2% 4.5%	0.282
Subtype Luminal A Luminal B HER2-enriched TNBC Unknown	133 131 31 89 9	33,8% 33,3% 7,9% 22,6% 2.3%	247 165 35 77 13	46% 30,7% 6.5% 14,3% 2.4%	< 0.0001
Ki67 <20% ≥ 20% Unknown	160 218 15	40,7% 55,5% 3.8%	267 250 20	49,7% 46,6% 3.7%	0.006
Histology Ductal Lobular Other Unknown	325 46 20 2	82.7% 11.7% 5.1% 0.5%	433 74 25 5	80.6% 13.8% 4.7% 0.9%	0.777
BRCA mutation BRCA1 BRCA2 Absence of mutation Not tested	10 6 90 287	2.5% 1.5% 22.9% 73%	12 10 87 428	2.2% 1.9% 16.2% 79.7%	0.551

Abbreviations: REC, Relative Eosinophil Count; N, Number; ER, Estrogen Receptor; PgR, Progesterone Receptor; TNBC, Triple-Negative Breast Cancer.

Table 2. REC in the group of 741 patients without relapse and in the group of 189 patients with relapse.

		Patients without relapse (n = 741)							Patients with relapse (n = 189)
		REC baseline	REC post-surgery	REC 1-y follow-up	REC 2-y follow-up	REC 5-y follow-up	REC 10-y follow-up	Friedman test	REC baseline	REC post-surgery	REC 1-y follow-up	REC 2-y follow-up	REC 5-y follow-up	REC 10-y follow-up	REC relapse	Friedman test
N pts		741	532	600	554	408	172		189	142	123	97	45	4	158
Median		1.7%	2.6%	2.6%	2.5%	2.6%	2.5%	<0.0001	1.4%	2.5%	2.5%	2.7%	2.5%	2.1%	1.5%	<0.0001
SD		1.917	2.379	1.,947	1.838	1.522	1.793		1.171	1.988	1.969	1.562	1.307	0.753	1.491
		p value							p value
Bonferroni–Dunn test	REC baseline	-	<0.0001	<0.0001	<0.0001	<0.0001	0.002	NA	-	<0.0001	<0.0001	<0.0001	0.002	1	1	NA
	REC post-surgery	<0.0001	-	1	1	0.127	0.869	NA	<0.0001	-	1	1	1	1	<0.0001	NA
	REC 1-y follow-up	<0.0001	1	-	1	1	1	NA	<0.0001	1	-	1	1	1	< 0.0001	NA
	REC 2-y follow-up	<0.0001	1	1	-	1	1	NA	<0.0001	1	1	-	1	1	<0.0001	NA
	REC 5-y follow-up	<0.0001	0.127	1	1	-	1	NA	0.002	1	1	1	-	1	0.004	NA
	REC 10-y follow-up	0.002	0.869	1	1	1	-	NA	1	1	1	1	1	-	1	NA
	REC relapse	NA	NA	NA	NA	NA	NA	NA	1	<0.0001	<0.0001	<0.0001	0.004	1	-	NA

Abbreviations: REC, Relative Eosinophil Count; y, years; N, Number; SD, Standard Deviation; NA, Not Applicable.

Table 3. REC variation in the cohort of patients without relapse according to subtype.

		REC baseline	REC post-surgery	REC 1y Follow-up	REC 2y follow-up	REC 5y follow-up	REC 10y follow-up	Friedman test
Luminal A	N	325	225	243	239	188	91
	Median	1.8%	2.7%	2.6%	2.7%	2.6%	2.6%	< 0.0001
	SD	1.882	2.580	1.710	1.757	1.578	1.733
Luminal B	N	236	181	206	187	129	45
	Median	1.6%	2.5%	2.8%	2.5%	2.9%	2.5%	< 0.0001
	SD	1.666	2.231	2.299	2.267	1.510	1,405
HER2-enriched	N	50	35	39	32	23	12
	Median	1.8%	2.8%	2.8%	2.1%	2.7%	3.4%	<0.0001
	SD	3.573	2.352	2.028	1.147	1.360	1.309
TNBC	N	115	81	102	89	62	19
	Median	1.4%	2.8%	2.5%	2.4%	2.1%	2.7%	< 0.0001
	SD	1.502	2.190	1.680	1.364	1.430	2.945

Abbreviations: REC, Relative Eosinophil Count; y, years; N, Number; SD, Standard Deviation; TNBC, Triple-Negative Breast Cancer.

Figure 1. TTF and BCSS according to baseline REC, RLC and ELP.

Table 4. REC variation in the cohort of patients with relapse according to subtype.

		REC baseline	REC post-surgery	REC 1-y follow-up	REC 2-y follow-up	REC 5-y follow-up	REC 10-y follow-up	REC relapse	Friedman test
Luminal A	N	55	39	40	38	24	1	43
	Median	1.5%	2.5%	2.4%	2.5%	2.25%	2.1%	1.6%	0.038
	SD	0.979	1.602	1.497	1.246	0.947	-	1.263
Luminal B	N	60	47	42	32	11	-	54
	Median	1.5%	2.1%	2.1%	2.7%	3%	-	1.2%	0.008
	SD	1.378	2.507	2.578	1.879	1.366	-	1.681
HER2-enriched	N	16	13	9	4	2	-	13
	Median	1.45%	2.6%	3.6%	3.6%	1.3%	-	0.9%	0.047
	SD	1.529	1.860	2.140	3.123	0.283	-	1.688
TNBC	N	50	37	27	19	5	2	42
	Median	1.4%	2.5%	2.8%	2.9%	3.4%	2.7%	1.7%	0.001
	SD	1.018	1.788	1.456	1.224	1.743	0.990	1.421

Abbreviations: REC, Relative Eosinophil Count; y, years; N, Number; SD, Standard Deviation; TNBC, Triple-Negative Breast Cancer.

Figure 2. Subgroup analysis for TTF and BCSS according to baseline REC.

Figure 3. Scatter dot plot of REC at different timepoints.